

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NEPTUNE GENERICS, LLC
Petitioner,

v.

CORCEPT THERAPEUTICS, INC.
Patent Owner.

Case IPR2018-01494
Patent No. 8,921,348 B2

**NEPTUNE GENERICS, LLC'S UPDATED MANDATORY
NOTICES PURSUANT TO 37 C.F.R. § 42.8**

Mail Stop: PATENT BOARD
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. § 42.8, Petitioner Neptune Generics, LLC, hereby submits the following updated information.

I. REAL PARTY-IN-INTEREST

Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies the following information: Neptune Generics, LLC; Niagara FundingCo, LLC; GKC Partners II, LP; GKC General Partner II, LP; Burford Capital Ireland DAC; GKC PII Holdings, LLC; Burford Capital Investment Management LLC; Burford Capital Holdings (UK) Limited; and Burford Capital Limited are the real parties in interest (collectively, “RPI”). Neptune Generics, LLC, a New York limited liability company, is 100% owned by Niagara FundingCo, LLC, a New York limited liability company, which itself is 100% owned by GKC Partners II, LP, a Delaware limited partnership. No other person (including any investor, limited partner, or member or any other person in any of Neptune Generics, LLC, Niagara FundingCo, LLC, GKC Partners II, LP, GKC General Partner II, LP, Burford Capital Ireland DAC, GKC PII Holdings, LLC, Burford Capital Investment Management LLC, Burford Capital Holdings (UK) Limited, or Burford Capital Limited) has authority to direct or control (i) the timing of, filing of, content of, or any decisions or other activities relating to this Petition or (ii) any timing, future filings, content of,

or any decisions or other activities relating to the future proceedings related to this Petition. All of the costs associated with this Petition are expected to be borne by Neptune Generics, LLC, Niagara FundingCo, LLC, GKC Partners II, LP, GKC General Partner II, LP, Burford Capital Ireland DAC, GKC PII Holdings, LLC, Burford Capital Investment Management LLC, Burford Capital Holdings (UK) Limited, and Burford Capital Limited.

Date: August 28, 2018

Respectfully Submitted,

By: /Kenneth M. Goldman/
Kenneth M. Goldman

Kenneth M. Goldman (Reg. No. 34,174)
MASSEY & GAIL LLP
50 E. Washington Street, Suite 400
Chicago, Illinois 60602
Telephone: (312) 283-1590
Fax: (312) 379-0467
Email: kgoldman@masseygail.com
Attorneys for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a true and correct copy of the above-captioned “Neptune Generics, LLC’S Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8” was served by electronic mail on August 28, 2018 upon Patent Owner’s lead and backup counsel at the following email addresses:

Robert Steinberg (Reg. No. 33,144)
Latham & Watkins LLP
555 Eleventh Street, NW, Ste. 1000
Washington, DC 20004-1304
bob.steinberg@lw.com

David P. Frazier (Reg. No. 47,576)
Latham & Watkins LLP
555 Eleventh Street, NW, Ste. 1000
Washington, DC 20004-1304
david.frazier@lw.com

Date: August 28, 2018

50 E. Washington Street
Suite 400
Chicago, Illinois 60602

/Kenneth M. Goldman/
Kenneth M. Goldman
Reg. No. 34,174
Attorney for Petitioner